Compare McKesson Corporation (MCK) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs United Microelectronics Corp — how do they compare? McKesson Corporation trades at $824.96 (market cap $97.35B), while United Microelectronics Corp trades at $21.2 (market cap $51.00B). The key difference: McKesson Corporation is the larger of the two by market cap, and United Microelectronics Corp pays the higher dividend (2.03%). Which is the better fit depends on your goals.
| MCK | UMC | |
|---|---|---|
Market Cap | $97.35B | $51.00B |
Sector | Health | Technology |
52-Week High | $995.69 | $28.02 |
52-Week Low | $659.01 | $6.58 |
Enterprise Value | $101.98B | $48.57B |
Dividend Yield | 0.39% | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
UMC trades at $20.41, down 3.95% for the day, with a bearish technical signal but oversold RSI readings. The company reported Q1 2026 EPS of $0.20, beating expectations, and maintains strong profitability with a 20.25% net margin. Recent news highlights mass production of silicon photonics ICs and a new 14nm eHV platform, signaling innovation in semiconductor technology.
Outlook is mixed: analyst consensus leans Hold (53%) amid high valuation multiples (P/E 34.5), but earnings beats and specialty tech growth offer upside. Risks include competitive pressures and margin compression from 32.1% in 2022 to 17.0% in 2025. Cash flow improved to $5.66B net in 2025, supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
